Sign in

BPTH on OTC

BIO-PATH HOLDINGS, INC.

American pharmaceutical preparations company based in Bellaire2

In its 2025 annual report the company says: “We are a clinical and preclinical stage oncology and obesity-focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease.”4 Its shares trade on OTC under the symbol BPTH.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with ORAGENICS INC, Lyell Immunopharma, Inc. or AXIM BIOTECHNOLOGIES, INC., or pick any stock.

  • TickerBPTH on OTC2
  • IndustryPharmaceutical Preparations2
  • HeadquartersBellaire, United States2
  • Incorporated inWY3
  • Business address4710 Bellaire Boulevard, Suite 210, Bellaire, Tx 774013
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5493000NXNRCVORQVB272
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered address108 Lakeland Avenue, 19901 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 56668472

See how the biggest companies compare on our leaderboards

We are a clinical and preclinical stage oncology and obesity-focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Our drug delivery and antisense technology, called DNAbilize®, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo , incorporated inside of a lipid bilayer having neutral charge. We believe this combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-like structures for delivery of the antisense drug substance into cells. In vivo , the DNAbilize® delivered antisense drug substances are systemically distributed throughout the body to allow for redu…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2018

-704.7%Return on equity5
-$6.1MFree cash flow6

Financial statements

Fiscal year2018
Revenue$07
Research and development$4.6M6
Operating expenses
Operating income-$8.6M6
Income before tax
Income tax$06
Net income-$8.6M6
Earnings per share
Earnings per share (diluted)
Shares (weighted, basic)
Shares (weighted, diluted)

Compare BIO-PATH HOLDINGS, INC. with another company

Corporate structure

BIO-PATH HOLDINGS, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of BIO-PATH HOLDINGS, INC.

  • BIO-PATH HOLDINGS, INC. Bellaire, Texas, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BIO-PATH HOLDINGS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.1M10 Dec 31, 2024$1.1M10 Dec 31, 2023−3.8%
Accumulated depreciation$1.1M10 Dec 31, 2024$1.0M10 Dec 31, 2023+1.0%
Property and equipment, net$23.0K10 Dec 31, 2024$76.0K10 Dec 31, 2023−69.7%
Operating-lease assets (leased space)$84.0K10 Dec 31, 2024$102.0K10 Dec 31, 2023−17.6%

Properties, in its own words

In April 2014, we entered into a lease agreement for approximately 3,000 square feet of office space for general and administrative purposes in Bellaire, Texas, which is part of the Houston metropolitan area. The term of the lease began on August 1, 2014 and was scheduled to terminate on July 31, 2019. In May 2019, we entered into an amendment to the lease agreement to extend the term of the lease to October 31, 2024. In October 2024, we entered into a second amendment to the lease agreement to extend the term of the lease to October 31, 2025.

In April 2016, we entered into a lease agreement for approximately 2,100 square feet of lab space located in Bellaire, Texas for research and development purposes. The term of the lease began on May 1, 2016 and was scheduled to terminate on April 30, 2019. In December 2018, we entered into an amendment to the lease agreement to extend the term of the lease to April 30, 2022. In January 2022, we exercised an option in the lease agreement amendment to extend the term of the lease to April 30, 2025.

The rest of Item 2

We do not own or lease any other real property that is materially important to our business. We believe that our current facilities are adequate for our current needs and that additional space will be available when and as needed.

Item 2 of the 10-K filed Mar 27, 2025.4

Leadership

Who has led BIO-PATH HOLDINGS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Peter Henry Nielsen2008–2024

President

  1. Peter Henry Nielsen2008–2024

Chief financial officer

  1. Peter Henry Nielsen2016–2024

Chief operating officer

  1. Ulrich W. Mueller2014–2017
2010201520202025
Board members and other officers (10)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorDouglas P, Morris named Nov 18, 2022 to Oct 22, 202423

Former names

  • BIO-PATH HOLDINGS INCDec 27, 2006 to Apr 5, 20243
  • OGDEN GOLF CO CORPMay 8, 2003 to Feb 19, 20083

Timeline

  1. Jul 16, 20268-K Unregistered sale of shares; Bylaws or fiscal year changed; Regulation FD disclosure24
  2. May 26, 20268-K Regulation FD disclosure; Other events25
  3. Mar 20, 20268-K Bylaws or fiscal year changed; Other events26
  4. Feb 24, 20268-K Change in control; Bylaws or fiscal year changed; Regulation FD disclosure27
  5. Nov 14, 20258-K Executive or director change; Other events28
  6. Oct 29, 20258-K Executive or director change29
  7. Aug 13, 20258-K Change of auditor30
  8. Jun 24, 20258-K Executive or director change; Other events31
  9. May 2, 20258-K Other events32
  10. Apr 29, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares33
  11. Mar 28, 20258-K Results of operations34
  12. Mar 28, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares35
  13. Dec 30, 2014Founded BIO-PATH HOLDINGS, INC. is founded2
  14. Sep 16, 2008New chief executive Peter Henry Nielsen becomes CEO11

Calendar

When it reported results

  1. Mar 28, 2025Reported quarterly or annual results34
  2. Nov 15, 2024Reported quarterly or annual results36
  3. Aug 15, 2024Reported quarterly or annual results37
  4. May 15, 2024Reported quarterly or annual results38
  5. Mar 8, 2024Reported quarterly or annual results39
  6. Nov 15, 2023Reported quarterly or annual results40
  7. Aug 15, 2023Reported quarterly or annual results41
  8. May 12, 2023Reported quarterly or annual results42

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

217 filings to the SEC since October 2021: 4 annual reports, 14 quarterly reports, 82 major events, 16 insider forms, 6 large holders, 5 private raises, 90 other. The latest 20:

  1. Aug 20, 20261-SA SEMI ANNUAL REPORT PURSUANT TO REGULATION A EDGAR
  2. Aug 5, 2026253G2 OFFERING CIRCULAR SUPPLEMENT NO. 1 EDGAR
  3. Jul 16, 20268-K EDGAR
  4. May 26, 20268-K EDGAR
  5. May 22, 202615-12G FORM 15 EDGAR
  6. May 20, 202610-Q EDGAR
  7. May 15, 2026NT 10-Q EDGAR
  8. May 1, 20261-K EDGAR
  9. Apr 28, 2026QUALIF EDGAR
  10. Apr 27, 2026CORRESP EDGAR
  11. Apr 1, 2026UPLOAD EDGAR
  12. Mar 25, 20261-A EDGAR
  13. Mar 20, 20268-K EDGAR
  14. Feb 25, 20261-Z EDGAR
  15. Feb 24, 20268-K EDGAR
  16. Jan 13, 202610-Q EDGAR
  17. Nov 17, 2025NT 10-Q EXTENSION EDGAR
  18. Nov 14, 20258-K EDGAR
  19. Oct 29, 20258-K EDGAR
  20. Aug 14, 202510-Q EDGAR

The 217 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2023Peter H. NielsenCEO,$575.0K$827.1K46
2022CFOPresident, Chairman, Director$555.0K$1.0M46

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Oct 8, 2024Raised $4 million in a private offering of equity Form D: 1 investor so far Form D
  2. Jun 3, 2024Raised $4 million in a private offering of equity Form D: 1 investor so far Form D
  3. Apr 18, 2024Raised $1.3 million in a private offering of securities Form D: 3 investors so far Form D
  4. Mar 25, 2024Raised $317,929 in a private offering of securities Form D: 1 investor so far Form D
  5. Nov 9, 2022Raised $2.3 million in a private offering of securities Form D: 5 investors so far Form D

SEC filer profile

How BIO-PATH HOLDINGS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBIO-PATH HOLDINGS, INC.1
  • CIK0001133818
  • Employer ID (EIN)87-06528704
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4710 Bellaire Boulevard, Suite 210, Bellaire, TX 774011
  • Phone(832) 742-13571
  • Shares outstanding50,297,451 as of May 20, 20269
  • Public float$5.0M as of Jun 30, 20244
  • AuditorErnst & Young, Houston, Texas PCAOB ID 42; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceMay 8, 20031
  • Filings730 in all: 8-K (295), 4 (77), 10-Q (53), 424B5 (28), CORRESP (26), UPLOAD (19), 10-K (17), D (17)1
    All 56 form types

    DEF 14A (17), 3 (14), 424B3 (14), DEFA14A (12), EFFECT (12), SC 13G (12), 10QSB (10), S-1 (9), S-1/A (9), SC 13G/A (9), S-3 (7), SB-2/A (7), NT 10-Q (6), PRE 14A (5), NT 10-K (4), RW (4), S-8 (4), 10KSB (3), 8-K/A (3), D/A (3), 1-A (2), 10-K/A (2), 10-Q/A (2), ARS (2), QUALIF (2), S-3/A (2), 1-A/A (1), 1-K (1), 1-SA (1), 1-Z (1), 10KSB/A (1), 10QSB/A (1), 15-12G (1), 25-NSE (1), 253G2 (1), 253G3 (1), 3/A (1), 424B4 (1), 8-A12B (1), 8-A12G (1), CERTNAS (1), DEFR14A (1), DEL AM (1), REGDEX (1), SB-2 (1), SC 13D (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2025
    Quarterly report (10-Q) May 20, 2026
    Proxy statement (DEF 14A) Oct 28, 2024
    Latest 8-K (8-K) Jul 16, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareBPTHNONE

From the cover page of the 10-K filed Mar 27, 2025 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks BIO-PATH HOLDINGS, INC. names in Item 1A of its 10-K filed Mar 27, 2025: 53 risks under these headings, as written.4

  • Risks Related to Our Business
  • We are a clinical stage biotechnology company with no significant revenue. We have incurred significant operating losses since our inception, and we expect to incur losses for the foreseeable future and may never achieve profitability.
  • We will continue to require substantial additional capital for the foreseeable future. If we are unable to raise additional capital when needed, we may be forced to delay, reduce or eliminate our drug development programs and commercialization efforts.
  • The report of our independent registered public accounting firm contains an emphasis of a matter regarding substantial doubt about our ability to continue as a going concern.
  • The pharmaceutical and biotechnology industry is highly competitive. If we are unable to compete effectively, our drug candidates may be rendered noncompetitive or obsolete.
  • Future collaboration arrangements to leverage our capabilities may not be successful.
  • If we are unable to attract and retain key management, scientific personnel and advisors, we may not successfully develop our drug candidates or achieve our other business objectives.
  • Our employees, agents, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with applicable regulatory standards and requirements.
  • We expect to expand our operations, including clinical trials, in the future and may face challenges in managing our growth, which may result in disruptions to our operations.
  • If we acquire or license technologies, resources or drug candidates, we will incur a variety of costs and may never realize benefits from the transaction.
  • Our business has a substantial risk of product liability claims. If we are unable to obtain or maintain appropriate levels of insurance, a product liability claim could adversely affect our business.
  • We are increasingly dependent on information technology systems to operate our business and a cyber-attack or other breach of our systems, or those of third parties on whom we may rely, could subject us to liability or interrupt the operation of our business.
The other 42 risks
  • Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
  • Provisions of our charter documents or Delaware law could delay or prevent an acquisition of our company, even if the acquisition would be beneficial to our stockholders, and could make it more difficult to change management.
  • We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology that may be similar to ours. If these companies develop technologies, including delivery technologies, or therapeutic candidates more rapidly than we do, or their technologies are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected.
  • We may be subject, directly or indirectly, to certain U.S. federal and state healthcare laws and regulations, such as anti-kickback, false claims laws, physician payment transparency laws or similar fraud and abuse laws, which could expose us to potential criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
  • Inadequate funding for the FDA, the SEC and other government agencies, or a work slowdown or stoppage at those agencies as part of a broader federal government shutdown, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • Our business and operations have been affected by and could be materially and adversely affected in the future by the effects of health epidemics and pandemics, including the evolving and ongoing effects of the COVID-19 pandemic.
  • Unstable market and economic conditions may have serious adverse effects on our ability to raise funds, which may cause delays, restructuring or cessation of our operations.
  • Risks Related to the Development of Our Drug Candidates
  • We must complete extensive clinical trials to demonstrate the safety and efficacy of our drug candidates. If we are unable to demonstrate the safety and efficacy of our drug candidates, we will not obtain the regulatory approval necessary to market our drug candidates, which would have an adverse effect on our business.
  • Delays in the commencement of clinical trials of our drug candidates could result in increased costs to us and delay our ability to generate revenues.
  • Delays in the completion of, or the termination of, clinical trials of our drug candidates could result in increased costs to us and could delay or prevent us from generating revenues.
  • If we are unable to obtain U.S. and/or foreign regulatory approval, we will be unable to commercialize our drug candidates.
  • Even if we are successful in obtaining regulatory approval to market a drug candidate, we, and our third-party manufacturer(s) will be, subject to extensive regulation by the FDA.
  • In addition to regulations in the U.S., we may be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products, if approved.
  • Changes in existing laws and regulations affecting the healthcare industry could increase our costs and otherwise adversely affect our business.
  • We rely on third parties to conduct clinical trials for our drug candidates, and their failure to timely and properly perform their obligations may result in costs and delays that prevent us from obtaining regulatory approval or successfully commercializing our drug candidates.
  • We may not be able to obtain or maintain orphan drug exclusivity for our product candidates.
  • Risks Related to Manufacturing Our Drug Candidates
  • We rely on third parties for manufacturing of our clinical drug supplies; our dependence on these manufacturers may impair the development of our drug candidates.
  • There are underlying risks associated with the manufacture of our drug candidates, which have never been manufactured in large scale. Furthermore, we anticipate continued reliance on third-party manufacturers if we are successful in obtaining marketing approval from the FDA or other regulatory agencies for any of our drug candidates.
  • Identification of previously unknown problems with respect to a drug candidate and/or a commercial product(s) with which any of our candidates are being tested or a manufacturer or facility involved in the production of any such candidate or commercial product may result in restrictions on the drug candidate, product, manufacturer or facility that could have a material adverse effect on the development of our drug candidate(s).
  • We may experience delays in the development of our drug candidates if the third-party manufacturers of our drug candidates cannot meet FDA requirements relating to current Good Manufacturing Practices.
  • Risks Related to Commercialization
  • If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our drug candidates, we may not generate product revenue.
  • If our future drugs do not achieve market acceptance, we may be unable to generate significant revenue, if any.
  • Even if we receive regulatory approval of any product candidate or therapy that we may develop, we will be subject to ongoing regulatory obligations, reporting requirements and continued regulatory review, which may result in significant additional expenses. If we fail to comply with regulatory requirements or experience unanticipated problems with our products or product candidates, we may be subject to substantial penalties, fines, delays, suspensions, refusals and withdrawals of approvals.
  • If third-party payors do not adequately reimburse patients for any of our drug candidates that are approved for marketing, they might not be purchased or used, and our revenues and profits will not develop or increase.
  • Risks Related to Intellectual Property
  • If our patent position does not adequately protect our drug candidates, others could compete against us more directly, which would harm our business.
  • If any third-party owners of intellectual property we may license in the future do not properly maintain or enforce the patents underlying such licenses, our competitive position and business prospects will be harmed.
  • If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed.
  • Litigation regarding patents, intellectual property and other proprietary rights may be expensive and time consuming. If we are involved in such litigation, it could cause delays in bringing drug candidates to market and harm our ability to operate.
  • Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information and may not adequately protect our intellectual property.
  • We may be subject to claims that our employees and contractors have wrongfully used or disclosed alleged trade secrets of their former employers.
  • Risks Related to Our Securities
  • Raising additional capital may cause dilution to existing stockholders, restrict our operations or require us to relinquish rights. Additionally, sales of a substantial number of shares of our common stock or other securities in the public market could cause our stock price to fall.
  • We may issue additional shares of our common stock in accordance with our equity incentive plans or upon exercise or conversion of outstanding securities that are exercisable for or convertible into shares of our common stock, which may cause dilution to existing stockholders.
  • The trading price of our common stock has been volatile and is likely to be volatile in the future.
  • Our common stock has been delisted from The Nasdaq Capital Market and there is no guarantee that our common stock will be regularly traded on the OTCQB Venture Market or other over-the-counter markets.
  • Our common stock is thinly traded and in the future may continue to be thinly traded, and our stockholders may be unable to sell at or near asking prices or at all if they need to sell their shares to raise money or otherwise desire to liquidate such shares.
  • Our certificate of incorporation grants our Board of Directors the power to designate and issue additional shares of common and/or preferred stock.
  • We do not anticipate paying cash dividends, and accordingly stockholders must rely on stock appreciation for any return on their investment in us.
  • Our management is required to devote substantial time and incur additional expense to comply with public company regulations.
  • Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on the price of our common stock.
  • Recent and future reverse stock splits may decrease the liquidity of our common stock and result in higher transaction costs.
  • Following a reverse stock split, the resulting market price of our common stock may not attract new investors, including institutional investors, and may not satisfy the investing requirements of those investors. Consequently, the trading liquidity of our common stock may not improve.
  • If securities or industry analysts do not publish research or reports about us, or if they adversely change their recommendations regarding our common stock, then our stock price and trading volume could decline.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46